Sun Pharma's IL-23 inhibitor tildrakizumab gains a psoriatic arthritis indication; the announcement cited no phase 3 efficacy figures.
|Articles|September 1, 2011
- Pharmaceutical Executive-09-01-2011
- Volume 0
- Issue 0
Pharmaceutical Executive Digital Edition - September 2011
From Many, One
Advertisement
Articles in this issue
about 15 years ago
Pharm Exec's 10th Annual Industry Auditabout 15 years ago
Pharma and Social Media: Ready to Make Nice?about 15 years ago
The Power of Product Development Partnershipabout 15 years ago
Front and Center in the Fight against TBabout 15 years ago
How to Recruit 70,000 People in One Yearabout 15 years ago
Innovating Around Innovationabout 15 years ago
India: Good Endings, Good Beginnings!about 15 years ago
Two Million Man Hoursabout 15 years ago
Rebates and Reformabout 15 years ago
Should the US Gamble with Risk Sharing?Advertisement
Related to this article
Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
2
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
3
FDA Approves Ilumya for Adults With Active Psoriatic Arthritis
4
Closing the Pediatric Evidence Gap
5